Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis

LI Long; KOU Junping

doi:10.11665/j.issn.1000-5048.20170301

Journal of China Pharmaceutical University > 2017 > 48(3): 251-258. > DOI: 10.11665/j.issn.1000-5048.20170301

LI Long, KOU Junping. Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis[J]. Journal of China Pharmaceutical University, 2017, 48(3): 251-258. DOI: 10.11665/j.issn.1000-5048.20170301

Citation:

PDF (1110 KB)

Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis

LI Long^1,2,
KOU Junping^1,2

More Information

Graphical Abstract

Abstract

Abstract

Arterial thrombosis(AT)is a common disease which usually causes acute myocardial infarction, ischemic stroke and other ischemic cardiovascular and cerebrovascular diseases, which shows high rates of morbidity and mortality, and has become a serious problem to human health. It is increasingly clear that the interactions among platelets, the endothelium and leukocytes are important throughout all stages of the atherothrombotic process. It is of great significance to search for therapeutic targets in the process of AT and developing the therapeutic drugs based on those newly discovered targets. This article reviews the research advances in the discovery of antithrombotic targets and the current situation of drug development based on those antithrombotic targets found in the recent 5 years, in order to provide some references or clues for the development of innovative drugs to prevent and treat AT.
- arterial thrombosis,
- atherosclerosis,
- therapeutic target,
- receptor,
- new drug development

FullText(HTML)

References (51)

References

[1]	Hu YW,Zhang P,Yang JY,et al.Nur77 decreases atherosclerosis progression in ApoE^(-/-) mice fed a high-fat/high-cholesterol diet[J].PLoS ONE,2014,9(1):e87313.
[2]	Yang P,Wei X,Zhang J,et al.Antithrombotic effects of Nur77 and Nor1 are mediated through upregulating thrombomodulin expression in endothelial cells[J].Arterioscler Thromb Vasc Biol,2016,36(2):361-369.
[3]	Xie X, Song X, Yuan S, et al. Histone acetylation regulates orphan nuclear receptor NR4A1 expression in hypercholesterolemia[J].Clin Sci,2015,129(12):1151-1161.
[4]	Lu Z,Zhang X,Li Y,et al.TLR4 antagonist attenuates atherogenesis in LDL receptor-deficient mice with diet-induced type 2 diabetes[J].Immumobiology,2015,220(11):1246-1254.
[5]	Ren M,Li R,Luo M,et al.Endothelial cells but not platelets are the major source of Toll-like receptor 4 in the arterial thrombosis and tissue factor expression in mice[J].Am J Physiol Regul Integr Comp Physiol,2014,307(7):R901-R907.
[6]	Opal SM,Pierre-Francois L,Bruno F,et al.Effect of eritoran,an antagonist of MD2-TLR4,on mortality in patients with severe sepsis:the ACCESS randomized trial[J].JAMA,2013,309(11):1154-1162.
[7]	Tsou TC,Liou SH,Yeh SC,et al.Crucial role of Toll-like receptors in the zinc/nickel-induced inflammatory response in vascular endothelial cells[J].Toxicol Appl Pharmacol,2013,273(3):492-499.
[8]	Balakumar P,Kathuria S.Submaximal PPARgamma activation and endothelial dysfunction:new perspectives for the management of cardiovascular disorders[J].Br J Pharmacol,2012,166(7):1981-1992.
[9]	Pasterk L,Lemesch S,Leber B,et al.Oxidized plasma albumin promotes platelet-endothelial crosstalk and endothelial tissue factor expression [J].Sci Rep,2016,6:22104.
[10]	Chen D,Xia M,Hayford C,et al.Expression of human tissue factor pathway inhibitor on vascular smooth muscle cells inhibits secretion of macrophage migration inhibitory factor and attenuates atherosclerosis in ApoE^-/- mice[J].Circulation,2015,131(15):1350-1360.
[11]	Zhai KF, Tang YM, Zhang YY, et al. NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3β-NF-κB signalling pathways in the endothelium[J].Thromb Haemost,2015,114(1):173-185.
[12]	Shi W,Mei H,Deng J,et al.The delivery of thrombi-specific nanoparticles incorporating oligonucleotides into injured cerebrovascular endothelium[J].Biomaterials,2013,34(16):4128-4136.
[13]	Wan W,Lionakis MS,Liu Q,et al.Genetic deletion of chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice[J].Cardiovasc Res,2013,97(3):580-588.
[14]	Wan W,Liu Q,Lionakis MS,et al.Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice[J].Cardiovasc Res,2015,6(3):478-487.
[15]	Majmudar MD,Keliher EJ,Heidt T,et al.Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice[J].Circulation,2013,127(20):2038-2046.
[16]	de Zeeuw D, Bekker P, Henkel E, et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy:a randomised trial[J].Lancet Diabetes Endocrinol,2015,3(9):687-696.
[17]	Gilbert J,Lekstrom-Himes J,Donaldson D,et al.Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region[J].Am J Cardiol,2011,107(6):906-911.
[18]	Pelham CJ,Keen HL,Lentz SR,et al.Dominant negative PPAR gamma promotes atherosclerosis,vascular dysfunction,and hypertension through distinct effects in endothelium and vascular muscle[J].Am J Physiol Regul Integr Comp Physiol,2013,304(9):R690-701.
[19]	Amato AA,Rajagopalan S,Lin JZ,et al.GQ-16,a novel peroxisome proliferator-activated receptor γ(PPARγ)ligand,promotes insulin sensitization without weight gain[J].J Biol Chem,2012,287(33):28169-28179.
[20]	Silva JC, César FA, de Oliveira EM, et al. New PPARγ partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr^(-/-) mice[J].Pharmacol Res,2016,104:49-60.
[21]	Shih CY,Chou TC.The antiplatelet activity of magnolol is mediated by PPAR-β/γ[J].Biochem Pharmacol,2012,84(6):793-803.
[22]	Van Gils JM,Derby MC,Fernandes LR,et al.The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques[J].Nat Immunol,2012,13(2):136-143.
[23]	Ramkhelawon B,Yang Y,Van Gils JM,et al.Hypoxia induces netrin-1 and Unc5b in atherosclerotic plaques:mechanism for macrophage retention and survival[J].Arterioscler Thromb Vasc Biol,2013,33(6):1180-1188.
[24]	Zhan B,Kong C,Guo K,et al.PKCα is involved in the progression of kidney carcinoma through regulating netrin-1/UNC5B signaling pathway[J].Tumour Biol,2013,34(3):1759-1766.
[25]	Gao X,Metzger U,Panza P,et al.A floor-plate extracellular protein-protein interaction screen identifies Draxin as a secreted netrin-1 antagonist[J].Cell Rep,2015,12(4):694-708.
[26]	Ungerer M,Li Z,Baumgartner C,et al.The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times[J].PLoS ONE,2013,8(8):e71193-e71193.
[27]	Ungerer M,Rosport K,Bültmann A,et al.Novel antiplatelet drug revacept(dimeric glycoprotein VI-Fc)specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans[J].Circulation,2011,123(17):1891-1899.
[28]	Jiang P,Loyau S,Tchitchinadze M,et al.Inhibition of glycoprotein VI clustering by collagen as a mechanism of inhibiting collagen-induced platelet responses:the example of losartan[J].PLoS ONE,2015,10(6):e0128744.
[29]	Lu WJ,Wu MP,Lin KH,et al.Hinokitiol is a novel glycoprotein VI antagonist on human platelets[J].Platelets,2014,25(8):595-602.
[30]	Chen W,Carvalho LP,Chan MY,et al.Fasxiator,a novel factor XIa inhibitor from snake venom,and its site-specific mutagenesis to improve potency and selectivity[J].J Thromb Haemost,2015,13(2):248-261.
[31]	Al-Horani RA,Ponnusamy P,Mehta AY,et al.Sulfated pentagalloylglucoside is a potent,allosteric,and selective inhibitor of factor XIa[J].J Med Chem,2013,56(3):867-878.
[32]	van Montfoort ML,Kuijpers MJ,Knaup VL,et al.Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques[J].Arterioscler Thromb Vasc Biol,2014,34(8):1668-1673.
[33]	Xu Y,Cai TQ,Castriota G,et al.Factor XIIa inhibition by infestin-4:in vitro mode of action and in vivo antithrombotic benefit[J].Thromb Haemost,2014,111(4):694-704.
[34]	Krupka J, May F, Weimer T, et al. The coagulation factor XIIa inhibitor rHA-infestin-4 improves outcome after cerebral ischemia/reperfusion injury in rats[J].PLoS ONE,2016,11(1):e0146783.
[35]	Baeriswyl V,Calzavarini S,Gerschheimer C,et al.Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy[J].J Med Chem,2013,56(9):3742-3746.
[36]	Larsson M,Rayzman V,Nolte MW,et al.A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk[J].Sci Transl Med,2014,6(222):222ra17.
[37]	Yau JW,Stafford AR,Liao P,et al.Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo[J].Acta Biomater,2012,8(11):4092-4100.
[38]	Su EJ,Geyer M,Wahl M,et al.The thrombomodulin analog solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model[J].J Thromb Haemost,2011,9(6):1174-1182.
[39]	Vicente CP, Weiler H, Di Cera E, et al. Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis[J].Thromb Res,2012,130(4):646-648.
[40]	Vincent JL,Ramesh MK,Ernest D,et al.A randomized,double-blind,placebo-controlled,Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin,ART-123,in patients with sepsis and suspected disseminated intravascular coagulation[J].Crit Care Med,2013,41(9):2069-2079.
[41]	Andersson HM,Siegerink B,Luken BM,et al.High VWF,low ADAMTS13,and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women[J].Blood,2012,119(6):1555-1560.
[42]	Pickens B, Mao Y, Li D, et al. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models[J].Blood,2015,125(21):3326-3334.
[43]	Kopi'c A,Benamara K,Piskernik C,et al.Preclinical assessment of a new recombinant ADAMTS-13 drug product(BAX930)for the treatment of thrombotic thrombocytopenic purpura[J].J Thromb Haemost,2016,14(7):1410-1419.
[44]	Holy EW, Jakob P, Eickner T, et al. PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation,but not re-endothelialization:potential implications for drug-eluting stent design[J].Eur Heart J,2014,35(12):808-820.
[45]	Nylander S,Kull B,Björkman JA,et al.Human target validation of phosphoinositide 3-kinase(PI3K)β:effects on platelets and insulin sensitivity,using AZD6482 a novel PI3Kβ inhibitor[J].J Thromb Haemost,2012,10(10):2127-2136.
[46]	Yi W,Li Q,Shen J,et al.Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161[J].PLoS ONE,2014,9(8):e102394.
[47]	Zheng Z,Pinson JA,Mountford SJ,et al.Discovery and antiplatelet activity of a selective PI3Kβ inhibitor(MIPS-9922)[J].Eur J Med Chem,2016,122:339-351.
[48]	Kwon HW,Shin JH,Cho HJ,et al.Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP(Ser(157))and dephosphorylation of PI3K and Akt[J].J Ginseng Res,2016,40(1):76-85.
[49]	Hahm E,Li J,Kim K,et al.Extracellular protein disulfide isomerase regulates ligand-binding activity of αMβ2 integrin and neutrophil recruitment during vascular inflammation[J].Blood,2013,121(19):3789-3800.
[50]	Wang L,Wu Y,Zhou J,et al.Platelet-derived ERp57 mediates platelet incorporation into a growing thrombus by regulation of the αIIbβ3 integrin[J].Blood,2013,122(22):3642-3650.
[51]	Cui G,Shan L,Guo L,et al.Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 f or prophylactic therapy[J].Sci Rep,2015,5:10353.

[1]	ZHU Song, JIANG Jing, LIU Yang, ZOU Wenyu, HU Pengwei, LU Yuting, SONG Min, HANG Taijun. Structural identification of the related substances of lorazepam tablets by LC-MS[J]. Journal of China Pharmaceutical University, 2021, 52(5): 555-565. DOI: 10.11665/j.issn.1000-5048.20210507
[2]	LIANG Fangmei, NI Yueling, WANG Lu, HANG Taijun, SONG Min. Structural identification of the related substances of fusidic acid by LC-MS[J]. Journal of China Pharmaceutical University, 2018, 49(3): 322-332. DOI: 10.11665/j.issn.1000-5048.20180311
[3]	YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
[4]	XU Yunhui, JIANG Xueyang, XU Jian, JIANG Renwang, ZHANG Jie, XIE Zijian, FENG Feng. Chemical constituents from Callicarpa kwangtungensis Chun[J]. Journal of China Pharmaceutical University, 2016, 47(3): 299-302. DOI: 10.11665/j.issn.1000-5048.20160309
[5]	CHEN Wenhua, ZOU Limin, ZHANG Fei, ZHANG Liandi, LIAO Mingyi, DING Li. Identification of the related substances in bendamustine hydrochloride[J]. Journal of China Pharmaceutical University, 2015, 46(3): 333-338. DOI: 10.11665/j.issn.1000-5048.20150312
[6]	MA Lin, ZHANG Rongfei, YU Shule, WU Zhengfeng, ZHAO Shouxun, Wang Lei, YE Wencai, ZHANG Jian, YIN Zhiqi. Chemical constituents of Fructus Gleditsiae Abnormalis[J]. Journal of China Pharmaceutical University, 2015, 46(2): 188-193. DOI: 10.11665/j.issn.1000-5048.20150209
[7]	CHANG Bo, XIAO Linjing, ZHANG Jian, ZHAO Shouxun, YE Wencai, YIN Zhiqi. Chemical constituents from Abies ernestii var.salouenensis[J]. Journal of China Pharmaceutical University, 2014, 45(1): 43-47. DOI: 10.11665/j.issn.1000-5048.20140107
[8]	RAO Ya-kun, DING Li, YU Yong. Structural identification of two major impurities in sodium levofolinate[J]. Journal of China Pharmaceutical University, 2012, 43(4): 350-354.
[9]	Chemical constituents from Senecio nemorensis.[J]. Journal of China Pharmaceutical University, 2010, 41(1): 26-28.
[10]	WANG Ying, YIN Hong-ping, CHEN Tao, WANG Min. Preliminary structural identification and protection on renal cell injury of acidic polysaccharide from Cordyceps sinensis[J]. Journal of China Pharmaceutical University, 2009, 40(6): 559-564.

Cited By

Get Citation

PDF

XML

Article views (1130) PDF downloads (3278)

Turn off MathJax

Article Contents

Abstract

References

Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis

Abstract

References

Related Articles

Catalog

Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content